

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (original) The invention relates to the discovery of the presence of endogenous proteins; nerve growth factor (NGF), myoglobin, Insulin, adenosine deaminase (ADA), including immunoglobulin E (IgE) in samples of human saliva.
2. (original) This invention relates to the introduction of use of saliva as a non-invasive source for detection and assay of endogenously present proteins; NGF, myoglobin, Insulin, ADA, including IgE.
3. (original) The invention discovered that people having high levels of IgE show higher levels in comparison to controls, of NGF, myoglobin, insulin and in asthma patients high level of ADA, disrupting the homeostasis for these proteins.
4. (original) Composition of synthetic LT-10 is advocated as a treatment for IgE implicated disorders. Synthetic LT-10 consists of ten amino acids: Leu Lys Ala Met Asp Pro Thr Pro Pro Leu.
5. (original) Composition of synthetic LT-10 as a treatment for having high level of IgE, causes decrease in level of IgE. Decrease in IgE level brings the homeostasis of other proteins to normal state which improves the symptoms in the afflicted people for asthma, depression, diabetes and various types of autoimmune diseases, such as erythematosus (SLE); Rheumatoid arthritis Sjogren's syndrome; Reiter's syndrome; Diabetes mellitus (insulin-dependent); Graves' disease; Addison's disease Hodgkin's disease etc.
6. (original) People having elevated level of IgE also show high level of NGF may be prone to the symptoms of neuropathy. Likewise high level of myoglobin may cause heart problems. Elevated

3

milligrams of the peptide are orally administered on a daily basis.

13. (previously amended) A method as in claim 10 wherein in the range of from about 0.2 to about 20 milligrams of the peptide are orally administered on a daily basis and the peptide is selected from the group consisting of

SEQ. ID. NO.: 4,  
SEQ. ID. NO.: 5,  
SEQ. ID. NO.: 1,  
SEQ. ID. NO.: 6, and  
SEQ. ID. NO.: 7.

14. (currently amended) A method as in claim 10 wherein said human has an elevated serum level of unbound IgE level prior to the step of administering the peptide.

15. (currently amended) A method as in claim 14 wherein said human further has an elevated serum level of NGF, Insulin, Myoglobin and/or ADA serum level prior to the step of administering the peptide and said elevated serum level of NGF, Insulin, Myoglobin and/or ADA is reduced following the step of administering the peptide.

16. (original) A method as in claim 14 further comprising assaying a saliva IgE level in said human.

17. (currently amended) A method as in claim 15 ~~14~~ comprising ~~diagnosing wherein said human further has~~ a condition selected from the group consisting of Asthma, Diabetes, Depression and Autoimmune Disease ~~in said human to which said peptide is to be administered.~~

18. (previously amended) A method as in claim 17 wherein the autoimmune disease is selected from the group consisting of Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren's

5

BEST AVAILABLE COPY